DataMEDS Scraps Amended LOI With Datavault, REBOOT and Partners, Citing Market Conditions
MEDS has more than doubled off its 52-week low of $0.823.
Summary
DataMEDS terminated the Second Amended and Restated LOI dated October 19, 2026 that would have brought in REBOOT Health AI, EOS, Scilex, HealthBridge Advisors and Datavault AI as IP in-licensing or acquisition partners paid in company stock. The company cites market conditions and says it owes no fees and will issue no shares tied to the deal. That unwinds the structure disclosed in the October 26 8-K, which had lifted partner ownership to roughly 89.5% and cut public holders to a sliver — so the near-term dilution overhang from that piece is gone, but so is the IP package. Two pieces survive: the October 13, 2026 exclusive REBOOT license for GLP-1 user management and the November 24, 2025 Datavault PharmacyChain smart-contract agreement, neither of which involved share issuance. Context matters here: a $26.1M Q2 loss, going-concern doubt and a Nasdaq equity deficiency already hang over the story, and losing a signed-up partner group on 'market conditions' reads poorly. Datavault AI (DVLT) is named as a counterparty but is not the primary subject.
At the time of this announcement, MEDS was trading at $1.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.1M. The 52-week trading range was $0.82 to $35.68. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: ACCESS Newswire.